HC Wainwright & Co. Maintains Buy on Ascendis Pharma, Lowers Price Target to $344
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $345 to $344.
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $345 to $344.